secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corbus Pharmaceuticals Holdings, Inc. (CRBP)
CIK:        0001595097
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0000950170-23-039409
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corbus Q2 net loss $8.8M vs $13.2M YoY; cash $36.6M; pipeline on track
----------------------------------------------------------------------

- Net loss of $8.8M ($2.05 diluted EPS) compared to $13.2M ($3.18) in Q2 2022; operating expenses down $4.1M.
- Cash, cash equivalents and investments $36.6M as of June 30, 2023; expected to fund operations through Q2 2024.
- CRB-701 Phase 1 dose escalation ahead of schedule in China; completion expected Q4 2023; US trial start accelerated to Q1 2024.
- Preliminary PK data for CRB-701 shows longer half-life and lower free MMAE vs published PADCEV data.
- CRB-601 IND submission on track for Q4 2023; first patient in Phase 1 expected H1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595097/000095017023039409/0000950170-23-039409-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595097/000095017023039409/crbp-20230808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-039409

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer